Skip to main content
SpringerLink
Log in

Colon Cancer

  • Chapter
International Manual of Oncology Practice

  • 1314 Accesses

Abstract

Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States [1]. Worldwide, bowel cancer is the third most commonly diagnosed cancer, with approximately 1.4 million cases per year, and the fourth leading cause of cancer death [2]. The global incidence of CRC varies by more than tenfold. The highest incidence rates are in Australia, New Zealand, Europe and North America, and the lowest rates are in Africa and South Central Asia. This geographic variation appears to be due to differences in the dietary and environmental exposures that are imposed on a background of genetically determined susceptibility [3]. In the United States the incidence and mortality for colorectal cancer decreased in the last 20 years as a result of cancer prevention and earlier diagnosis [4]. However, this is not true worldwide, because access to diagnosis and treatment is heterogeneous, resulting in late diagnosis, advanced stage disease and poor treatment in some countries [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. National Cancer Institute (2014) Available from: http://nci.org. Accessed September 2014

  2. Ferlay J (2013) Cancer incidence and mortality worldwide. Available from: http://globocan.iarc.fr. Accessed December 2013

  3. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69

    Article  PubMed  Google Scholar 

  4. Siegel R, Ward E, Braeley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212–236

    Article  PubMed  Google Scholar 

  5. Chan AT, Giovannucci EL (2010) Primary prevention of colorectal cancer. Gastroenterology 138:2029

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  6. Hemminik K, Chen B (2004) Familial risk for colorectal cancers are mainly due to heritable causes. Cancer Epidemiol Biomarkers Prev 13:1253–1256

    Google Scholar 

  7. Burt RW, DiSario JA, Cannon-Albright L (1995) Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med 46:371

    Article  PubMed  CAS  Google Scholar 

  8. Lynch TH, Smyrk TC, Watson P et al (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an up-to-date review. Gastroenterology 104:1535

    PubMed  CAS  Google Scholar 

  9. Beamer LC, Grant ML, Espenschied CR et al (2012) Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 30:1058–1063

    Article  PubMed Central  PubMed  Google Scholar 

  10. Ward RL, Hicks S, Hawkins NJ (2013) Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J Clin Oncol 11:1380–1385

    Google Scholar 

  11. EGAPP Working Group (2009) Reccomendations from the EGAPP working group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11:35–41

    Google Scholar 

  12. National Comprehensive Cancer Network (2014) Available from: www.nccn.org

  13. Imperiale TF, Glowinski EA, Lin-Cooper C et al (2008) Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med 359:1218–1224

    Article  PubMed  CAS  Google Scholar 

  14. Lieberman DA, Weiss DG, Harford WV et al (2007) Five-year colon surveillance after screening colonoscopy. Gastroenterology 133:1077–1085

    Article  PubMed  Google Scholar 

  15. Singh H, Turner D, Xue L et al (2006) Risk developing colorectal cancer following a negative colonoscopy examination: evidence for a 10 year interval between colonoscopies. JAMA 295:2366–2373

    Article  PubMed  CAS  Google Scholar 

  16. Brenner H, Chang-Claude J, Seiler CM et al (2006) Does a negative screening colonoscopy ever need to be repeated? Gut 55:1145–1150

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  17. Levin B, Lieberman DA, McFarland et al (2008) Screening and surveillance for early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58:130–160

    Article  PubMed  Google Scholar 

  18. Engel C, Rahner N, Schulmann K et al (2010) Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 8:174

    Article  PubMed  Google Scholar 

  19. Vansen HF, Abdirahman M, Brohet R et al (2010) One to 2-year intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 138:2300

    Article  Google Scholar 

  20. Vasen HF, Moslein G, Alonso A et al (2008) Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 57:704

    Article  PubMed  CAS  Google Scholar 

  21. Boyle T, Keegel T, Bull F et al (2012) Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. J Natl Cancer Inst 104:1548

    Article  PubMed  Google Scholar 

  22. Lee JE, Chan AT (2011) Fruit, vegetables, and folate: cultivating the evidence for cancer prevention. Gastroenterology 141:16

    Article  PubMed Central  PubMed  Google Scholar 

  23. Kim Y-I (2000) AGA technical review: impact of dietary fiber on colon cancer occurrence. Gastroenterology 18:1235–1257

    Article  Google Scholar 

  24. Wu S, Feng B, Li K et al (2012) Fish consumption and colorectal cancer risk in humans: a systematic review and meta-analysis. Am J Med 125:551

    Article  PubMed  Google Scholar 

  25. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaudessade S, Baron JA (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256

    Article  PubMed  CAS  Google Scholar 

  26. Burn J, Gerdes AM, Macrae F et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomized controlled trial. Lancet 378:2081–2087

    Article  PubMed Central  PubMed  Google Scholar 

  27. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Boober SV, Robinson CR, Offerhaus GJ (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313

    Article  PubMed  CAS  Google Scholar 

  28. Majumdar SR, Fletcher RH, Evans AT (1999) How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol 94:3039

    Article  PubMed  CAS  Google Scholar 

  29. American Society of Gastrointestinal Endoscopy (2000) Appropriate use of gastrointestinal endoscopy. Gastrointest Endosc 52:831–837

    Article  Google Scholar 

  30. Atkin W, Dadswell E, Wooldrage K, Kralj-Hans I, von Wagner C, Edwards R, Yao G, Kay C, Burling D, Faiz O, Teare J, Lilford RJ, Morton D, Wardle J, Halligan S (2013) SIGGAR investigators. Computed tomographic colonography versus colonoscopy for investigations of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentric randomized trial. Lancet 381:1194

    Article  PubMed  Google Scholar 

  31. Balthazar EJ, Megibow AJ, Hulnick D, Naidch DP (1988) Carcinoma of the colon: detection and preoperative staging by CT. AJR Am J Roentgenol 150:301

    Article  PubMed  CAS  Google Scholar 

  32. McAndrew MR, Saba AK (1999) Efficacy of routine preoperative computed tomography scan in colon cancer. Am Surg 65:205

    PubMed  CAS  Google Scholar 

  33. Hundt W, Braunschweig R, Reiser M (1999) Evaluation of spiral CT in staging of colon and rectum carcinoma. Eur Radiol 9:78

    Article  PubMed  CAS  Google Scholar 

  34. National Cancer Institute. Colon cancer PDQ. http://www.cancer.gov/cancertopics

  35. Ling-Hui Xu, San-Jun Cai, Guo-Xiang Cai, Wei-Jun Peng (2011) Imaging diagnosis of colorectal liver metastases. World J Gastroenterol 17:4654–4659

    Google Scholar 

  36. Kirchin MA, Pirovano GP, Spinazzi A (1998) Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol 33:798–809

    Article  PubMed  CAS  Google Scholar 

  37. Hamm B, Staks T, Muhler A, Bollow M, Taupitz M, Frenzel T, Wolf KJ, Weinmann HJ, Lange L (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MRI contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792

    Article  PubMed  CAS  Google Scholar 

  38. Whiteford MH, Yee LF et al (2000) Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 43:759

    Article  PubMed  CAS  Google Scholar 

  39. Flamen P, Hoekstra OS, Homans F et al (2001) Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal câncer: the utility of positron emission tomography (PET). Eur J Cancer 37:862

    Article  PubMed  CAS  Google Scholar 

  40. Flanagan FL, Dehdashti F, Ogunbiyi OA et al (1998) Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 227:319

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  41. Niekel MC, Bipat S, Stokern J (2010) Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PRET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 257:674

    Article  PubMed  Google Scholar 

  42. Moulton CA, Gu CS, Law CH, Tandan VR, Hart R, Quan D, Fairfull Smith, Jalink DW, Husien M, Serrano PE, Hendler AL, Haider MA, Ruo L, Gulenchym KY, Finch T, Julian JA, Levine MN, Gallinger S (2014) Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA 311(18):1863–1869

    Article  PubMed  CAS  Google Scholar 

  43. American Joint Committee on Cancer (AJCC) (2010) Colon and rectum. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC cancer staging manual, 7th edn. Springer, New York, pp 143–164

    Google Scholar 

  44. Compton CC, Greene FL (2004) The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 54(6):295–308

    Article  PubMed  Google Scholar 

  45. Chen VW, Hsieh MC, Charlton ME, Ruiz BA, Karlitz J, Altekruse SF, Ries LA, Jessup JM (2014) Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system. Cancer 120(Suppl 23):3793–3806

    Article  PubMed Central  PubMed  Google Scholar 

  46. Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Miedema B, Ota D (2001) Guidelines 2000 for colon and rectal cancer surgery. J Natl Inst 93:583–596

    Article  CAS  Google Scholar 

  47. Fleshman JW, Wexner SD, Anvari M, La Tulippe JF, Birnbaum EH, Kodner IJ et al (1999) Laparoscopic vs open abdominoperineal resection for cancer. Dis Colon Rectum 42:930–939

    Article  PubMed  CAS  Google Scholar 

  48. Stocchi L, Nelson H (1998) Laparoscopic colectomy for colon cancer: trial update. J Surg Oncol 68:255–267

    Article  PubMed  CAS  Google Scholar 

  49. Enker WE, Laffer UT, Block GE (1979) Enhanced survival of patients with colon and rectal cancer is based upon wide anatomic resection. Ann Surg 190:350–360

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  50. Fleshman J, Sargent DJ, Green E et al (2007) Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg 246:655

    Article  PubMed  Google Scholar 

  51. Jayne DG, Thorpe HC, Copeland J et al (2010) Five-year follow-up of the Medical Research Council CLASSIC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg 97:1638

    Article  PubMed  CAS  Google Scholar 

  52. NIH consensus conference on adjuvant therapy for patients with colon and rectal cancer (1990) JAMA 264:1444–1450

    Google Scholar 

  53. Nivatvongs S (2002) Surgical management of malignant colorectal polyps. Surg Clin North Am 82(5):959–966

    Article  PubMed  Google Scholar 

  54. Hackelsberger A, Fruhmorgen P, Weiler H, Heller T, Seeliger H, Junghanns K (2003) Endoscopic polypectomy and management. Gastroenterology 41:703

    Article  Google Scholar 

  55. Ueno H et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127:385–394

    Article  PubMed  Google Scholar 

  56. Moertel CG, Fleming TR, Macdonald JS et al (1995) Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 13:2936

    PubMed  CAS  Google Scholar 

  57. Quasar Collaborative Group, Gray R, Barnwell J et al (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 370:2020

    Article  Google Scholar 

  58. Schippinger W, Samonigg H, Schaberl-Moser R et al (2007) A prospective randomized phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 97:1021

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  59. Figueredo A, Charette ML, Maroun J et al (2004) Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 22:3395

    Article  PubMed  Google Scholar 

  60. Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  61. Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204

    Article  PubMed  CAS  Google Scholar 

  62. Moertel CG, Fleming TR, Macdonald JS et al (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122:321

    Article  PubMed  CAS  Google Scholar 

  63. Porschen R, Bermann A, Löffler T et al (2001) Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 19:1787

    PubMed  CAS  Google Scholar 

  64. Wolmark N, Rockette H, Mamounas E et al (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553

    PubMed  CAS  Google Scholar 

  65. André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109

    Article  PubMed  Google Scholar 

  66. Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465

    Article  PubMed  CAS  Google Scholar 

  67. Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696

    Article  PubMed  CAS  Google Scholar 

  68. Des Guetz G, Nicolas P, Perret GY et al (2010) Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 46:1049

    Article  PubMed  Google Scholar 

  69. Biagi JJ, Raphael MJ, Mackillop WJ et al (2011) Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 305:2335

    Article  PubMed  CAS  Google Scholar 

  70. Tournigand C, André T, Bonnetain F et al (2012) Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly (between ages 70 and 75 years) with colon cancer: a subgroup analyses of the Multicenter International Study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol 30:3353–3360

    Article  PubMed  CAS  Google Scholar 

  71. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD) (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 371:1007–1016

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  72. Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Van Cutsem E, Scheithauer W, Lutz MP, Nordlinger B, EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK (CRUK), Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD) (2012) Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg 255:534–539

    Article  PubMed  Google Scholar 

  73. Chen-Chen Wang, Jin Li (2012) An update on chemotherapy of colorectal liver metastases. World J Gastroenterol 8:25–33

    Google Scholar 

  74. Adam R (2003) Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 14(Suppl 2):ii13–ii16

    PubMed  Google Scholar 

  75. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A (2008) The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 12:iii–ix

    Article  PubMed  CAS  Google Scholar 

  76. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L et al (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:1670–1676

    Article  PubMed  CAS  Google Scholar 

  77. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  PubMed  Google Scholar 

  78. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, Stroh C, Celik I, Koralewski P (2008) KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 26:a4000

    Article  Google Scholar 

  79. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL et al (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377:2103–2114

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  80. Garufi C, Torsello A, Tumulo S, Mottolese M, Campanella C, Zeuli M, Lo Re G, Pizzi G, Ettorre GM, Sperduti I (2009) POCHER (preoperative chemotherapy for hepatic resection) study with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J Clin Oncol 27:ae15020

    Google Scholar 

  81. Ychou M, Desseigne F, Thezenas S, Viret F, Mineur L, Assenat E, Bleuse J, Kramar A, Portales F, Samalin E (2009) Preliminary results of a of a mutli-center phase II trial evaluating cetuximab in combination with FOLFIRINOX (LV5FU irinotecan oxaliplatin) as first-line treatment of metastatic colorectal cancer (mCRC). ASCO Gastrointest Cancers Symp:a450

    Google Scholar 

  82. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J (2009) Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer first BEAT and the randomised phase-III NO16966 trial. Br J Cancer 101:1033–1038

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  83. Walter H, Thomas AL (2013) Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review. Br J Cancer 108:2417–2418

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  84. Falcone A, Masi G, Loupakis F, Vasile E, Ciarlo A, Cavaciocchi D, Amoroso D, Puglisi M, Fea E, Brunetti I (2008) FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab in the first-line treatment of metastatic colorectal cancer: a phase II study by the G.O.N.O. group. J Clin Oncol 26:a4031

    Google Scholar 

  85. Jäger E, Heike M, Bernhard H et al (1996) Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 14:2274

    PubMed  Google Scholar 

  86. Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19:2282

    PubMed  CAS  Google Scholar 

  87. Meta-analysis Group In Cancer, Piedbois P, Rougier P et al (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301

    Google Scholar 

  88. QUASAR collaborative group (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 370:2020–2029

    Article  Google Scholar 

  89. Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136

    PubMed  CAS  Google Scholar 

  90. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041

    Article  PubMed  CAS  Google Scholar 

  91. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. Lancet Oncol 15:1065

    Article  PubMed  CAS  Google Scholar 

  92. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697

    Article  PubMed  CAS  Google Scholar 

  93. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP, MRC COIN Trial Investigators (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial. Lancet 377:2103

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  94. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335

    Article  PubMed  CAS  Google Scholar 

  95. Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, Salvatore L, Cremolini C, Stasi I, Brunetti I, Fabbri MA, Puglisi M, Trenta P, Granetto C, Chiara S, Fioretto L, Allegrini G, Crinò L, Andreuccetti M, Falcone A (2011) Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst 103:21

    Article  PubMed  Google Scholar 

  96. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, CORRECT Study Group (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, phase 3 trial. Lancet 381:303

    Article  PubMed  CAS  Google Scholar 

  97. Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, Benson AB III (2013) Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society Of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 31:4465–4470

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro de Pesquisas Clínicas em Oncologia, Hospital Evangélico de Cachoeiro de Itapemirim, Rua Mario Imperial, 47 2° Andar, 29308-014, Cachoeiro de Itapemirim, ES, Brazil

    José Zago Pulido, Sabina Bandeira Aleixo, Narelle de Jesus Parmanhani & José Antonio Guimarães Aleixo

Authors
  1. José Zago Pulido
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sabina Bandeira Aleixo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Narelle de Jesus Parmanhani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José Antonio Guimarães Aleixo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sabina Bandeira Aleixo .

Editor information

Editors and Affiliations

  1. Medical Oncology, University of Algarve, Faro, Portugal

    Ramon Andrade de Mello

  2. edificio 7, ala nascente, 3º andar, University of Algarve, Dept Cie Biomed edificio 7, ala nascente, 3º andar, Faro, Portugal

    Álvaro Tavares

  3. Medical Oncology, University of Athens, Athens, Greece

    Giannis Mountzios

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Pulido, J.Z., Aleixo, S.B., de Jesus Parmanhani, N., Aleixo, J.A.G. (2015). Colon Cancer. In: de Mello, R., Tavares, Á., Mountzios, G. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-21683-6_12

Download citation

Publish with us

Policies and ethics

Search

Navigation